Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 10—October 2013
Dispatch

Primary Multidrug-Resistant Mycobacterium tuberculosis in 2 Regions, Eastern Siberia, Russian Federation

Svetlana Zhdanova1, Scott K. Heysell1Comments to Author , Oleg Ogarkov, Galina Boyarinova, Galina Alexeeva, Suporn Pholwat, Elena Zorkaltseva, Eric R. Houpt, and Eugeniy Savilov
Author affiliations: Russian Academy of Medical Sciences, Irkutsk, Russian Federation (S. Zhdanova, O. Ogarkov, E. Savilov); University of Virginia, Charlottesville, Virginia, USA (S.K. Heysell, G. Boyarinova, S. Pholwat, E.R. Houpt); Regional TB-Prevention Dispensary, Irkutsk (O. Ogarkov, E. Zorkaltseva); Research Practice Center for Phthisiatry, Yakutsk, Russian Federation (G. Alexeeva); State Medical Continuing Education Academy, Irkutsk (E. Zorkaltseva, E. Savilov)

Main Article

Table 2

Resistance mutations in Mycobacterium tuberculosis from 51 patients from Irkutsk and Yakutia, Russian Federation*

Drug, locus
Mutation, no. (% total) Drug resistance, no. (% with mutation)
Amino acid change
Nucleotide change
Isoniazid
katG Ser315Thr 28 (55) 25 (89)
Ser315Thr/Trp321Cys 4 (7) 4 (100)
Trp321Cys 1 (2) 1 (100)
Thr322Ala 1 (2) 0
No mutation 8 (16) 3 (38)
No amplification 9 (18) 8 (89)
inhA C(−15)T 3 (6) 3 (100)
T(−8)A 1 (2) 1 (100)
G (−13)T 1 (2) 1 (100)
No mutation 41 (80) 32 (78)
No amplification 4 (7) 4 (100)
Rifampin, rpoB Ser531Leu 19 (37) 15 (79)
Ser531Leu/Thr481Ala 1 (2) 0
Ser 531Leu/Thr480Ile 2 (4) 2 (100)
Ser531Tryp/Val456Gly 1 (2) 1 (100)
Gln513Lys 2 (4) 2 (100)
Leu533Pro 1 (2) 1 (100)
His516Tyr 1 (2) 1 (100)
Leu511Pro 1 (2) 0
No mutation 22 (43) 6 (27)
No amplification 1 (2) 0
Fluoroquinolones, gyrA Not performed
Ser95Thr 46 (90)†
Asp94Gly 1 (2)
Asp94Ala 1 (2)
Ala90Val 1 (2)
No amplification 2 (4)
Ethambutol, embB Asp354Ala 3 (6) 1 (33)
Asp354Ala/Gly406Asp 1 (2) 0
Met306Val 3 (6) 3 (100)
Met306Ile 3 (6) 3 (100)
Gly406Ser 3 (6) 2 (67)
Gly406Ala 2 (4) 0
Gly406Cyst 1 (2) 1 (100)
No mutation 25 (49) 9 (36)
No amplification 10 (20) 3 (30)
Not performed
Pyrazinamide, pncA Gly113Phe 3 (6)§ G338T and C96T
Leu19Arg 2 (4)§ T56G
Gly113Phe/Arg121 Leu 1 (2)§ G338T and C96T/ G362T
Arg121Leu 1(2)§ G362T
Gln10Pro 1 (2) A29C
Val7Gly 1 (2) T20G /G481C
Ala161Pro/ Val155Ala 1 (2)§ G203A
His137Asp/ Frameshift 1 (2)§ T464C/ insertion C480
Tryp68Stop 1 (2)§ C409G
Frameshift 1 (2)§ deletionG5
No mutation 8 (14)
No amplification 30 (59)
Kanamycin
rrs A1401G 4 (57) 3 (75)
C1443G 3 (43) 1 (33)
No mutation 35 12 (34)
No amplification 9 3 (33)
eis G(−10)A 4 (44) 2 (50)¶
C(−14)T 1 (11) 1 (100)¶
C(−15)G 2 (22) 0
C(−14)G 1 (11) 0
C(−12)T 1 (11) 0
No mutation 36 11
No amplification 6 3 (50)

*Blank cells indicate not applicable. All inhA mutations were associated with a Ser315Thr mutation in katG except for 1 isolate in which katG did not amplify.
†Previously demonstrated not to be associated with phenotypic resistance.
‡Excluding 25 silent pncA mutations (Ser32Ser most common, n = 14).
§Mutations in pncA not previously reported. Conventional susceptibility testing was unavailable for pyrazinamide and the fluoroquinolones.
¶For all 3 mutations of eis associated with kanamycin resistance, rrs was wild type.

Main Article

1These authors contributed equally to this article.

Page created: September 16, 2013
Page updated: September 16, 2013
Page reviewed: September 16, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external